OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS)(also called velocardiofacial syndrome).

Trial Profile

OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS)(also called velocardiofacial syndrome).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2012

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2012 Eli Lilly added as associations as reported in the European Clinical Trials Database record.
    • 21 Apr 2012 Planned end date changed from 3 Nov 2012 to 7 Sep 2013 as reported by European Clinical Trials Database record.
    • 21 Apr 2012 Actual initiation date changed from 3 May 2011 to 7 March 2012 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top